FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1946476244> ?p ?o ?g. }

• W1946476244 endingPage "2305" @default.
• W1946476244 startingPage "2300" @default.
• W1946476244 abstract "The standard sunitinib schedule, 4 weeks on, followed by 2 weeks off (4/2 schedule), is associated with troublesome toxicities, and maintenance of adequate sunitinib dosing and drug levels, which are essential for achieving an optimal treatment outcome, is challenging. The objective of this study was to investigate the efficacy and safety of an alternative sunitinib dosing schedule of 2 weeks on and 1 week off (2/1 schedule) compared with the standard sunitinib schedule of 4 weeks on and 2 weeks off (4/2 schedule).In this multicenter, randomized, open-label, phase II trial, treatment-naïve patients with clear-cell type metastatic renal cell carcinoma (mRCC) were randomly assigned to 4/2 or 2/1 schedules after stratification by Memorial Sloan Kettering Cancer Center risk group and the presence or absence of measurable lesions. The primary end point was the 6-month failure-free survival (FFS) rate, determined by intention-to-treat analysis.From November 2007 to February 2014, 76 patients were accrued, and 74 were eligible. FFS rates at 6 months were 44% with the 4/2 schedule (N = 36) and 63% with the 2/1 schedule (N = 38). Neutropenia (all grades, 61% versus 37%; grade 3-4, 28% versus 11%) and fatigue (all grades, 83% versus 58%) were more frequently observed with schedule 4/2. There was a strong tendency toward a lower incidence of stomatitis, hand-foot syndrome, and rash with schedule 2/1. Objective response rates (ORRs) were 47% in schedule 2/1 and 36% in schedule 4/2. With a median follow-up of 30.0 months, the median time to progression (TTP) was 12.1 months in schedule 2/1 and 10.1 months in schedule 4/2.Sunitinib administered with a 2/1 schedule is associated with less toxicity and higher FFS at 6 months than a 4/2 schedule, without compromising the efficacy in terms of ORR and TTP (NCT00570882)." @default.
• W1946476244 created "2016-06-24" @default.
• W1946476244 creator A5000929257 @default.
• W1946476244 creator A5001412099 @default.
• W1946476244 creator A5002821481 @default.
• W1946476244 creator A5009502217 @default.
• W1946476244 creator A5045648382 @default.
• W1946476244 creator A5052223687 @default.
• W1946476244 creator A5077382108 @default.
• W1946476244 creator A5079540101 @default.
• W1946476244 creator A5084264299 @default.
• W1946476244 creator A5089425787 @default.
• W1946476244 date "2015-11-01" @default.
• W1946476244 modified "2023-09-26" @default.
• W1946476244 title "RandomizEd phase II trial of Sunitinib four weeks on and two weeks off versus Two weeks on and One week off in metastatic clear-cell type REnal cell carcinoma: RESTORE trial" @default.
• W1946476244 cites W1967487178 @default.
• W1946476244 cites W2039698853 @default.
• W1946476244 cites W2061581498 @default.
• W1946476244 cites W2086735022 @default.
• W1946476244 cites W2112075556 @default.
• W1946476244 cites W2113788015 @default.
• W1946476244 cites W2116949558 @default.
• W1946476244 cites W2117125017 @default.
• W1946476244 cites W2143782771 @default.
• W1946476244 cites W2145046367 @default.
• W1946476244 cites W2149456801 @default.
• W1946476244 cites W2149613039 @default.
• W1946476244 cites W2155319477 @default.
• W1946476244 cites W2164886552 @default.
• W1946476244 cites W2462198268 @default.
• W1946476244 cites W4229769653 @default.
• W1946476244 doi "https://doi.org/10.1093/annonc/mdv357" @default.
• W1946476244 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26347107" @default.
• W1946476244 hasPublicationYear "2015" @default.
• W1946476244 type Work @default.
• W1946476244 sameAs 1946476244 @default.
• W1946476244 citedByCount "90" @default.
• W1946476244 countsByYear W19464762442015 @default.
• W1946476244 countsByYear W19464762442016 @default.
• W1946476244 countsByYear W19464762442017 @default.
• W1946476244 countsByYear W19464762442018 @default.
• W1946476244 countsByYear W19464762442019 @default.
• W1946476244 countsByYear W19464762442020 @default.
• W1946476244 countsByYear W19464762442021 @default.
• W1946476244 countsByYear W19464762442022 @default.
• W1946476244 countsByYear W19464762442023 @default.
• W1946476244 crossrefType "journal-article" @default.
• W1946476244 hasAuthorship W1946476244A5000929257 @default.
• W1946476244 hasAuthorship W1946476244A5001412099 @default.
• W1946476244 hasAuthorship W1946476244A5002821481 @default.
• W1946476244 hasAuthorship W1946476244A5009502217 @default.
• W1946476244 hasAuthorship W1946476244A5045648382 @default.
• W1946476244 hasAuthorship W1946476244A5052223687 @default.
• W1946476244 hasAuthorship W1946476244A5077382108 @default.
• W1946476244 hasAuthorship W1946476244A5079540101 @default.
• W1946476244 hasAuthorship W1946476244A5084264299 @default.
• W1946476244 hasAuthorship W1946476244A5089425787 @default.
• W1946476244 hasBestOaLocation W19464762441 @default.
• W1946476244 hasConcept C126322002 @default.
• W1946476244 hasConcept C141071460 @default.
• W1946476244 hasConcept C143998085 @default.
• W1946476244 hasConcept C203092338 @default.
• W1946476244 hasConcept C2777063308 @default.
• W1946476244 hasConcept C2777288759 @default.
• W1946476244 hasConcept C2777472916 @default.
• W1946476244 hasConcept C2778570526 @default.
• W1946476244 hasConcept C2779051857 @default.
• W1946476244 hasConcept C2779490328 @default.
• W1946476244 hasConcept C29730261 @default.
• W1946476244 hasConcept C535046627 @default.
• W1946476244 hasConcept C71924100 @default.
• W1946476244 hasConceptScore W1946476244C126322002 @default.
• W1946476244 hasConceptScore W1946476244C141071460 @default.
• W1946476244 hasConceptScore W1946476244C143998085 @default.
• W1946476244 hasConceptScore W1946476244C203092338 @default.
• W1946476244 hasConceptScore W1946476244C2777063308 @default.
• W1946476244 hasConceptScore W1946476244C2777288759 @default.
• W1946476244 hasConceptScore W1946476244C2777472916 @default.
• W1946476244 hasConceptScore W1946476244C2778570526 @default.
• W1946476244 hasConceptScore W1946476244C2779051857 @default.
• W1946476244 hasConceptScore W1946476244C2779490328 @default.
• W1946476244 hasConceptScore W1946476244C29730261 @default.
• W1946476244 hasConceptScore W1946476244C535046627 @default.
• W1946476244 hasConceptScore W1946476244C71924100 @default.
• W1946476244 hasIssue "11" @default.
• W1946476244 hasLocation W19464762441 @default.
• W1946476244 hasLocation W19464762442 @default.
• W1946476244 hasOpenAccess W1946476244 @default.
• W1946476244 hasPrimaryLocation W19464762441 @default.
• W1946476244 hasRelatedWork W1971020867 @default.
• W1946476244 hasRelatedWork W2056402925 @default.
• W1946476244 hasRelatedWork W2072245035 @default.
• W1946476244 hasRelatedWork W2108045918 @default.
• W1946476244 hasRelatedWork W2171237277 @default.
• W1946476244 hasRelatedWork W2322617799 @default.
• W1946476244 hasRelatedWork W2544140097 @default.
• W1946476244 hasRelatedWork W3151554875 @default.
• W1946476244 hasRelatedWork W4205243027 @default.

• next